Spinal Muscular Atrophy
Lancet 371:2120-2133, Lunn,M.R. &Wang,C.H., 2008
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Primary Central Nervous System Vasculitis: Analysis of 101 Patients
Ann Neurol 62:442-451,430, Salvarani,C.,et al, 2007
Amyotrophic Lateral Sclerosis
Lancet 369:2031-2041, Mitchell,J.D. & Borasio,G.D., 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Palliative Care for Patients With Amyotrophic Lateral Sclerosis
JAMA 298:207-216,248, Mitsumoto,H. &Rabkin,J.G., 2007
Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis With Dementia; Correlation With MR and Pathologic Examinations
AJNR 28:1505-1510, Matsusue,E.,et al, 2007
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
Clinicopath Conf., Paraneoplastic Cerebellar Degeneration Due to Anti-Yo Antibodies From Breast Cancer
NEJM 356:612-620, Case 4-2007, 2007
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
NMO-IgG in the Diagnosis of Neuromyelitis Optica
Neurol 68:1076-1077, Jarius,S.,et al, 2007
Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007
Course and Outcome of Acute Limbic Encephalitis With Negative Voltage-Gated Potassium Channel Antibodies
JNNP 78:391-394, Samarasekera,S.R., et al, 2007
Paraneoplastic Vasculitis of Central Nervous System Presenting as Recurrent Cryptogenic Stroke
Int J Clin Oncol 12:155-159, Taccone,F.S.,et al, 2007
Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006
Frontotemporal Lobar Degeneration with Motor Neuron Disease
Arch Neurol 63:489-490, Clark,C.M. &Forman,M.S., 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Revised Diagnostic Criteria for Neuromyelitis Optica
Neurol 66:1485-1489, Wingerchuk,D.M.,et al, 2006
Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006
Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006
Obsessive-Compulsive Disorder
BMJ 333:424-429, Heyman,I.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Cerebral Sinovenous Thrombosis in the Neonate
Arch Neurol 63:405-409, Fitzgerald,K.C.,et al, 2006
Brain Abnormalities in Neuromyelitis Optica
Arch Neurol 63:390-396, Pittock,S.J.,et al, 2006
Adrenoleukodystrophy
JAMA 294:3131-3134, Moser,H.W.,et al, 2005
Randomized, Controlled Trial of Cannabis-Based Medicine in Central Pain in Multiple Sclerosis
Neurol 65:812-819,788, Rog,D.J.,et al, 2005
Overdiagnosis of Multiple Sclerosis and Magnetic Resonance Imaging Criteria
Ann Neurol 58:781-783, Nielsen,J.M.,et al, 2005
Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria"
Ann Neurol 58:840-846, Polman,C.H.,et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Hemiplegic ALS:Mills Syndrome
Neurol 64:1984-1985, Rajabally,Y.A.,et al, 2005
Clinicopath Conf,Encephalomyelitis Due to West Nile Virus and CLL, Case 22-2005
NEJM 353:287-295, Hollande,H.,et al, 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
A Serum Autoantibody Marker of Neuromyelitis Optica: Distinction from Multiple Sclerosis
Lancet 364:2106-2112, Lennon,V.A.,et al, 2004
West Nile Virus Infection in the United States
Arch Neurol 61:1190-1195, Tyler,K.L., 2004
Susac Syndrome:Report of Four Cases and Review of the Literature
AJNR 25:382-388,351, Do,T.H.,et al, 2004
ALS Corticospinal Degeration on DWI
Neurol 62:1834, Cabello,J.P.,et al, 2004
Role of Magnetic Resonance Imaging Within Diagnostic Criteria for Multiple Sclerosis
Ann Neurol 56:273-278, Miller,D.H.,et al, 2004
New Diagnostic Criteria for Multiple Sclerosis
Neurol 60:27-30,6, Tintore,M.,et al, 2003
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Rasmussen's Encephalitis
Neurol 60:422-425, Granata,T.,et al, 2003
Prognosis in Amyotrophic Lateral Sclerosis
Neurol 60:813-819, del Aguila,M.A.,et al, 2003
Neuromyelitis Optica:What It Is and What It Might Be
Lancet 361:889-890, Weinshenker,B.G., 2003
Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003